We already know that B works, see results P2. So why would CTIX's stock be any more less than it is today just because it takes more than 1 dose? Especially considering the PPS did not go up with the Poly acquisition.
The fact that bacteria does not build up resistance to B is another factor why it is better than Cubist drug.
Perhaps I'm totally off base NR, but is your post borderline soft bashing, especially when the PPS is hurting? Is your other handle, DR J. ??? :)